Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.46 |
| ▸ | S100B | P04271 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | SCN4A | P35499 | 1/20 | 0.33 |
| ▸ | MC3R | P41968 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7655945 | 0.87 | ALDH1A1 (0.44) | CD44S100BCYP3A4TDP1TSHR | |
| SCHEMBL10935007 | 0.84 | ALDH1A1 (0.40) | CD44S100BCYP3A4TDP1TSHR | |
| SCHEMBL18509851 | 0.76 | CD44 (0.52) | CD44CYP3A4TDP1TSHRPIK3CA | |
| SCHEMBL6472907 | 0.75 | CYP3A4 (0.52) | CD44S100BCYP3A4TDP1TSHR | |
| SCHEMBL3117753 | 0.75 | TRPA1 (0.46) | CYP3A4ALDH1A1MAPK1MAPTLMNA | |
| SCHEMBL20421624 | 0.75 | CD44 (0.42) | CD44S100BCYP3A4TDP1TSHR | |
| SCHEMBL11884085 | 0.74 | S100B (0.41) | S100BCYP3A4TDP1TSHRALDH1A1 | |
| SCHEMBL4636717 | 0.74 | S100B (0.48) | S100BCYP3A4TDP1TSHRPIK3CA | |
| Hydrochloric Acid SCHEMBL6472903 | 0.73 | CYP3A4 (0.50) | CD44S100BCYP3A4TDP1TSHR | |
| SCHEMBL10391695 | 0.73 | TAAR1 (0.36) | S100BCYP3A4TDP1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0506366-B1 | High performance curable PPO/monomeric epoxy compositions with tin metal salt compatibilizing agent | GEN ELECTRIC (US) | 1997-12-29 | — | — | EP | claimed |
| US-7256177-B2 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-20050215488-A1 | Such as 5-propyl-azepane-2-carboxylic acid [2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; for prevention and treatment of mycobacterial, mycoplasmal or chlamydia infection; microbiocides | VICURON PHARMACEUTICALS INC. | 2005-09-29 | — | — | US | disclosed |
| EP-0487084-B1 | Image forming method and apparatus | CANON KK (JP) | 2002-01-30 | — | — | EP | disclosed |
| US-5864406-A | Method and apparatus for forming halftone images on organic-silver-salt-based printing plates | CANON KABUSHIKI KAISHA (JP) | 1999-01-26 | — | — | US | disclosed |
| US-5533452-A | Method of peeling a release film from a photosensitive plate blank | CANON KABUSHIKI KAISHA (JP) | 1996-07-09 | — | — | US | disclosed |
| EP-0491457-A1 | Image forming method and apparatus | CANON KABUSHIKI KAISHA (JP) | 1992-06-24 | — | — | EP | disclosed |
| EP-0487260-A1 | Printing method | CANON KABUSHIKI KAISHA (JP) | 1992-05-27 | — | — | EP | disclosed |
| EP-0487084-A2 | Image forming method and apparatus | CANON KABUSHIKI KAISHA (JP) | 1992-05-27 | — | — | EP | disclosed |
| US-5073791-A | IMAGE FORMING DEVICE | CANON KABUSHIKI KAISHA (JP) | 1991-12-17 | — | — | US | disclosed |
| EP-0410287-A2 | Polyphosphazene derivatives containing carbonyl groups and variously alkylated tertiary amino groups | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1991-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215488-A1 | Such as 5-propyl-azepane-2-carboxylic acid [2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; for prevention and treatment of mycobacterial, mycoplasmal or chlamydia infection; microbiocides | PAM, MLYCD, PPT1 | CD44 4762/4885S100B 4767/4885CYP3A4 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.